Or positron emission tomography edpillson.com.

PET, or positron emission tomography, nuclear medicine imaging technology, three-dimensional representations of the metabolic states in the human body is produced, allowing researchers the path and amount of drug accumulation in study participants to see edpillson.com more info . PET imaging study showed that Tyrima entered and left the brain achieves high plasma concentrations and exhibited a favorable pharmacokinetic half-life. Additional results will be submitted for presentation at a future scientific meeting or for inclusion in a peer-reviewed medical publication.

CeNeRx BioPharma Finalizes planned phase II trials for its novel antidepressant Tyrima Using Innovative Brain Imaging Study initiateCeNeRx BioPharma, into the clinical company developing and commercializing innovative treatments for diseases of the central nervous system, announced plans to move its lead candidate Tyrima is in Phase II trials advance, for the treatment of depression and anxiety. This milestone is on the positive results of the Tyrima Phase I program reported and and the recent completion of PET brain imaging studies showing that Tyrima the CNS and exhibits excellent pharmacokinetic and pharmacodynamic properties penetrates based. Tyrima is a selective and reversible member of a new class of drugs known as RIMAs or reversible inhibitors of monoamine oxidase A . – ‘Tyrima must the potential be the first triple-action antidepressant with a safety profile capable of treating a broad patient population, in addition are very pleased with the promising properties Tyrima in these PET imaging studies were satisfied, ‘said Barry Brand, Chief Executive Officer of CeNeRx. ‘These encouraging results of our for for Phase II Tyrima trials in patients with major initiate depression later ‘ ‘.

read full text

These remarkable results been by the 57 th Annual Meeting of American Society for Hygiene and Tropical Medicine & sanitation in the New Orleans, Louisiana, is presented. The results show the benefit of treatment, to actual global against a neglected disease from 400 to 500,000 people each year and the cause of death by more than 1 million people are, largely kids, unfortunately, is under 5 in sub-Saharan Africa under contract.